Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A
Drugmakers have been focused on buying late-stage assets with larger revenue potential to replace older blockbuster drugs that have fallen out of favor.
Enter the email associated with your account and we'll send you a link to reset your password.